Midatech Ltd., an Abingdon, Oxford, UK-based company that designs, develops, and manufactures nanomedicines, has raised £6.3m in funding.
The company intends to use the capital to strengthen and diversify its product development portfolio, especially in oncology, with the clinical development of chemotherapeutic gold nanoparticles designed to target ovarian, lung and breast carcinoma and of therapeutic cancer vaccines in SynTara, a joint venture with Immunotope Inc.
Founded in 2000 and led by CEO and Chairman Prof. Thomas Rademacher, Midatech designs, synthesizes and manufactures biocompatible nanoparticles, which can be used to create a wide variety of products with novel characteristics, functions and applications for a number of industry segments including life sciences, electronics and fine chemicals.
The company has its manufacturing facility – Midatech Biogune S.L. – in Bilbao, Spain while Basel, Switzerland-based PharMida AG is responsible for clinical development of Midatech’s products.